Nutriband Inc. NTRB
4.93 USD -0.07 (-1.40%)
As ofNov 20, 2026, 2:45 PM EST
4.84 Day range 5.22
2.80 52-week range 9.19
- YTD
- +8.59%
- 1 year
- -2.18%
No chart data for this range yet.
- Market cap
- 59.93M
- Revenue (ttm)
- 2.02M
- EPS (ttm)
- -0.53
- Shares out
- 11.11M
- Forward P/E
- -17.30
- YTD return
- +8.59%
- 1-year return
- -2.18%
- Volume
- 2.98K
- Avg volume
- 71.54K
- Open
- 4.95
- Previous close
- 5.00
- Day's range
- 4.84 – 5.22
- 52-week range
- 2.80 – 9.19
- Beta
- 0.42
Key statistics
- 50-day average
- 5.30
- 200-day average
- 5.09
- Enterprise value
- 44.16M
- Price / sales
- 21.92
- Price / book
- 5.47
- Revenue growth
- -14.30%
- Free cash flow
- -1.55M
- Total cash
- 8.35M
- Total debt
- 527.92K
- Return on equity
- -60.41%
- Short % of float
- 1.00%
Fundamental scorecard
6 of 25 checks passed on NTRB’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jul 31, 2026.
Financials — quick view
NTRB Revenue — quarterly 437.51K
NTRB Net income — quarterly -880.56K
NTRB EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 3, 2024 | Oct 1, 2024 | 0.00 | -0.12 | — | — |
| Sep 3, 2024 | Jul 1, 2024 | 0.00 | -0.12 | — | — |
| May 31, 2024 | Apr 1, 2024 | 0.00 | -0.21 | — | — |
| Apr 30, 2024 | Jan 1, 2024 | 0.00 | -0.16 | — | — |
| Dec 12, 2023 | Oct 1, 2023 | 0.00 | -0.22 | — | — |
| Sep 11, 2023 | Jul 1, 2023 | 0.00 | -0.11 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 26, 2022 | Small Cap Consumer Research | main | — | Buy |
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nutriband.com
News
Your note
Sign in to keep a note on NTRB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MELNIK SERGUEI | President | Stock Gift | Mar 5, 2023 | 827,999 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.86% | 118,063 | 469.89K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.91% | 58,063 | 231.09K | Sep 29, 2024 |
| UBS Group AG | 0.32% | 20,352 | 81.00K | Sep 29, 2024 |
| Avantax Advisory Services, Inc. | 0.29% | 18,678 | 74.34K | Sep 29, 2024 |
| State Street Corporation | 0.27% | 17,266 | 68.72K | Sep 29, 2024 |
| Farther Finance Advisors, Llc | 0.25% | 16,014 | 63.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.13% | 71,575 | 284.87K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.69% | 43,788 | 174.28K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 29,333 | 116.75K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 9,882 | 39.33K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 7,260 | 28.89K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.11% | 6,718 | 26.74K | Oct 30, 2024 |
